 |
|
|
| |
A Phase 3 Study of Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate in Patients With HBeAg-Negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results
|
| |
| |
Reported by Jules Levin
EASL 2016 Barcelona April 22-24
Maria Buti1, Edward Gane2, Wai Kay Seto3, Henry L.Y. Chan4, Wan-Long Chuang5,
Tatjana Stepanova6, Aric-Josun Hui7, Young-Suk Lim8, Rajiv Mehta9, Harry L.A. Janssen10,11, Subrat K. Acharya12, John F. Flaherty13, Benedetta Massetto13, Andrea Cathcart13,
Phillip Dinh13, G. Mani Subramanian13, John G. McHutchison13, Calvin Pan14,
Maurizia Brunetto15, Namiki Izumi16, Patrick Marcellin17
1Hospital General Universitari Vall d'Hebron, Barcelona, Spain; 2Auckland Clinical Studies, Auckland, New Zealand; 3Queen Mary Hospital, Hong Kong, China; 4The Chinese University of Hong Kong, China; 5Kaohsiung Medical University Hospital, Taiwan; 6Modern Medicine Clinic, Moscow, Russia; 7Alice Ho Miu Ling Nethersole Hospital, Hong Kong, China; 8Asan Medical Center, Seoul, South Korea; 9Nirmal Hospital Private Limited, Surat, Gujarat, India; 10Toronto Western Hospital, Toronto, Ontario, Canada; 11Erasmus Medical Center, Rotterdam, Netherlands; 12All India Institute of Medical Sciences Delhi, New Delhi, India; 13Gilead Sciences, Inc., Foster City, CA, USA; 14New Discovery, LLC, New York, NY, USA; 15University Hospital of Pisa, Italy; 16Musashino Red Cross Hospital, Tokyo, Japan; 17Hopital Beaujon, Clichy, France
|
| |
|
|
|
|
|
